Intraocular injection conbercept is safe and effective to improve vision, relieve symptoms for patients suffered from choroidal neovascularization secondary to punctate inner choroidopathy

Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN85678307

Enrollment

Registered

2017-05-11

Start date

2015-05-01

Completion date

Unknown

Last updated

2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Active subfoveal or juxatoveal CNV secondary to punctate inner choroidopathy Eye Diseases Active subfoveal or juxatoveal CNV secondary to punctate inner choroidopathy

Interventions

Participants who require treatment for CNV receive a single intravitreal injection of 0.5mg conbercept at baseline. Reinjection is given if intraretinal edema or subretinal fluid is observed with opti

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Active subfoveal or juxatoveal CNV secondary to PIC, where PIC was defined as multiple, small yellow-white lesions or atrophy in the posterior pole that had typical manifestations on optical coherence tomography (OCT) images 2. PIC lesions observed around the CNV. CNV was considered active if leakage within the lesion are observed with fluorescein angiography (FA) or intraretinal edema or subretinal fluid was observed with OCT 3. Adults aged 18 and older

Exclusion criteria

Exclusion criteria: 1. CNV was secondary to other causes, such as AMD, PCV, fundus angioid streaks, or trauma 2. Presence of any other ophthalmic diseases 3. Prior treatment of CNV, including thermal laser photocoagulation, submacular surgery, intravitreal any anti-VEGF drugs, and photodynamic therapy (PDT) 4. Administration immunosuppressants or corticosteroids (local or systemic) in observation period 5. Presence of systemic diseases or pregnancy

Design outcomes

Primary

Measure	Time frame
1. Visual outcomes (best-corrected visual acuity BCVA) are measured using an eye test at baseline, and month one, two, three, four, five and six 2. Anatomical outcomes (CRT, subretinal or intraretinal fluid build up) is measured manually based on patients’ OCT images using a scale of Heidelberg software at baseline and month one, two, three, four, five and six 3. Angiographic leakage is measured by fluorescein angiography (FA) images at month one, two, three, four, five and six 4. Number of treatments is measured using patient interviews at month one, two, three, four, five and six 5. Adverse events are measured using patient interviews at month one, two, three, four, five and six month	—

Measure

Time frame

1. Visual outcomes (best-corrected visual acuity BCVA) are measured using an eye test at baseline, and month one, two, three, four, five and six 2. Anatomical outcomes (CRT, subretinal or intraretinal fluid build up) is measured manually based on patients’ OCT images using a scale of Heidelberg software at baseline and month one, two, three, four, five and six 3. Angiographic leakage is measured by fluorescein angiography (FA) images at month one, two, three, four, five and six 4. Number of treatments is measured using patient interviews at month one, two, three, four, five and six 5. Adverse events are measured using patient interviews at month one, two, three, four, five and six month

—

Secondary

Measure	Time frame
1. The change in the size of choroidal neovascularization (CNV) is measured using patients’ fluorescein angiography (FA) images at baseline and month six 2. The change in number or size of punctate inner choroidopathy (PIC) lesions is measured using patients’ indocyanine green angiography images at baseline and month six	—

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 9, 2026